Safety and Effectiveness of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance in Japan

Kazuo Fujihara, Shinya Hirota, Muneyoshi Kudo, Hideaki Hida, Satoshi Yuki, Takashi Narisawa, Kyoko Kato · 2026

Read Safety and Effectiveness of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance in Japan by Kazuo Fujihara, Shinya Hirota, Muneyoshi Kudo, Hideaki Hida, Satoshi Yuki, Takashi Narisawa, Kyoko Kato (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13615213.txt.

Description

Kazuo Fujihara and co-authors report interim safety and effect data for a relapse prevention drug in a Japanese nerve disease, in work from twenty twenty-six. The disease, NMOSD, attacks the optic nerve and spinal cord in relapses. The drug inebilizumab is approved in Japan for patients with a key antibody.

Nationwide post market tracking covered more than two hundred patients who started the drug from twenty twenty-one to twenty twenty-three. About a third had drug reactions, with infections most common and two deaths that could not be cleared of drug links. Relapse rates fell to a quarter of the prior level after starting. Steroid doses and add on immune drugs dropped sharply by one year. No new safety flags appeared.

Catalog record

CREATORKazuo Fujihara, Shinya Hirota, Muneyoshi Kudo, Hideaki Hida, Satoshi Yuki, Takashi Narisawa, Kyoko Kato
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE43 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13615213

Browse the full library · About the Tower of Babel